zoledronic acid / Generic mfg. - LARVOL DELTA

Top 20 Research Studies of 2025 for Primary Care Physicians. (PubMed, Am Fam Physician) - "Women with normal bone density given zoledronic acid every 5 years have fewer fractures...For patients with provoked venous thromboembolism and at least one ongoing risk factor, 12 months of apixaban is better than 3 months. Clopidogrel is slightly more effective than aspirin for the secondary prevention of myocardial infarction and stroke over 3 years...Duloxetine, milnacipran, and pregabalin provide meaningful pain reduction in adults with fibromyalgia...A meta-analysis of platelet-rich plasma injections for knee osteoarthritis concluded that high-quality studies found no meaningful pain improvement. Using an oral challenge to rule out sulfonamide allergy is safe when used with a risk assessment tool."

Journal • Review • Allergy • Atherosclerosis • Atrial Fibrillation • Breast Cancer • Cardiovascular • CNS Disorders • Depression • Fibromyalgia • Hypotension • Immunology • Infectious Disease • Influenza • Long-acting Reversible Contraceptives • Musculoskeletal Diseases • Musculoskeletal Pain • Myocardial Infarction • Novel Coronavirus Disease • Oncology • Osteoarthritis • Pain • Psychiatry • Respiratory Diseases • Rheumatology • Solid Tumor • Vaginitis • Venous Thromboembolism

Acute Orbital Inflammation following Neridronate Therapy: A Case Report. (PubMed, Case Rep Ophthalmol) - "While most reported cases involve agents such as zoledronate or alendronate, reports associated with neridronate remain exceedingly rare...Following the initiation of high-dose oral prednisone (1 mg/kg/day), the patient exhibited rapid clinical improvement within 48 h and near-complete radiologic resolution by 15 days. This case underscores the importance of recognizing neridronate-associated orbital inflammation as a potential adverse reaction, even following intramuscular injection. Despite its severe presentation, the condition typically demonstrates a rapid and favorable response to systemic corticosteroid therapy."

Journal • Dermatology • Inflammation • Musculoskeletal Pain • Ocular Inflammation • Ophthalmology • Pain • Scleritis • CRP

Real world outcomes comparing denosumab and zoledronic acid in patients with metastatic prostate cancer with bone metastasis: A propensity score matched analysis from global federated health research network (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Randomized Phase II Study of Hypofractionated Stereotactic Radiotherapy With Concurrent 5-fluorouracil /Capecitabine With or Without Zoledronic Acid in Locally Advanced Pancreatic Ductal Adenocarcinoma (ASTRO 2026) - "Materials/ After pathologic confirmation and staging, patients with borderline resectable or locally advanced PDAC received induction FOLFIRINOX or gemcitabine/nab-paclitaxel per standard of care... SBRT with capecitabine and Zometa is feasible and safe in locally advanced PDAC. While Zometa did not significantly improve locoregional control or survival, a higher proportion of long-term survivors in the Zometa arm warrants further study with the addition of immune checkpoint inhibitors."

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma

Real world outcomes comparing denosumab and zoledronic acid in patients with metastatic thyroid cancer with bone metastases: A propensity score matched analysis from global federated health research network (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Real world outcomes comparing denosumab and zoledronic acid in patients with metastatic renal cell cancer with bone metastases: A propensity score matched analysis from global federated health research network (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Colosplenic Fistula Without Intraluminal Pathology: Look Beyond the Mucosa (ACG 2026) - "Hypercalcemia was managed with IV fluids, calcitonin, and zoledronic acid...Colonoscopy at the splenic flexure demonstrates an 8-mm fistulous opening characterized by surrounding mucosal edema and focal luminal narrowing. Notably, there is no evidence of a discrete intraluminal mass, overt ulceration, or active bleeding at the site."

Acute Kidney Injury • Colorectal Adenocarcinoma • Colorectal Cancer • Crohn's disease • Endocrine Disorders • Gastroenterology • Hematological Malignancies • Immunology • Inflammatory Bowel Disease • Lymphoma • Metabolic Disorders • Nephrology • Renal Disease • Solid Tumor

The third-year results of denosumab sequential therapy trial: An extension of a randomized clinical trial. (PubMed, J Formos Med Assoc) - P4 | "These findings suggest that an alternating regimen of denosumab and zoledronate may be a viable strategy for managing osteoporosis, effectively mitigating the rebound effect while maintaining BMD gains. The observed benefits of reduced BTMs in the intervention group highlight the long-lasting therapeutic effects of zoledronate. Further research is necessary to confirm these results and determine this approach's long-term safety and cost-effectiveness."

Clinical • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Discovery and Structural Basis of Zoledronic Acid as a Potent SPS-Targeting Herbicide. (PubMed, Plant Cell Environ) - "ZOL showed good herbicidal activity against S. viridis, D. sanguinalis, V. persica, and C. album at 1000 g a.i./ha. Together, this work establishes ZOL as a mechanistically distinct SPS inhibitor and provides a structural basis for the development of competitive SPS-inhibiting herbicides."

Journal

Risk factors for drug-related cachexia: an analysis based on the FDA adverse event reporting system (FAERS) from 2004 to 2025. (PubMed, Front Pharmacol) - "The drugs with stronger signals were low calcium peritoneal dialysis solution lactate G15 (ROR 495.67, 95% CI 336.94-729.18), Kaletra (ROR 10.44, 95% CI 7.98-13.65), and nivolumab (ROR 15.29, 95% CI 13.65-17.13). The drugs with a higher number of reported cases were nivolumab (319 cases), paclitaxel (160 cases), and Zometa (131 cases)...Cachexia is more likely to occur in the initial stage of drug treatment and has a high mortality rate. Continuous regulatory review and label updates of the safety information of relevant medications should be promoted."

Adverse events • Journal • Cachexia • Metabolic Disorders • Oncology

Skeletal-Related Events and Treatment-Associated Toxicities with Bone-Directed Therapy Use in Transplant Eligible Newly Diagnosed Multiple Myeloma (IMS 2026) - "Prior to transplant, 222 patients (46.2%) received bone-directed therapy, including zoledronic acid in 165 patients (74.3%) and denosumab in 57 patients (25.7%). In patients with MM undergoing ASCT, SREs were uncommon following anti-myeloma and bone-directed therapy, although new osteolytic lesions remained the predominant skeletal complication. Treatment-related toxicities were infrequent, while ONJ remained an important adverse event with prolonged therapy. Further studies are needed to optimize the duration of bone-directed therapy and balance skeletal protection with toxicity risk."

Acute Kidney Injury • CNS Disorders • Endocrine Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • Transplantation

Bortezomib-Based Regimen Significantly Reduces Bone Resorption Rate Compared to Lenalidomide-Based in Newly Diagnosed Elderly Multiple Myeloma Patients: Results from the Italian Real Phase IV Trial (IMS 2026) - P4 | "This prospective multicenter study longitudinally evaluated several cytokines and chemokines and biomarkers of bone remodeling in elderly newly diagnosed (ND) MM patients included in the Real MM trial (NCT03829371 funded by the Italian Medicines Agency AIFA - Independent Research), designed to compare Bortezomib-Melphalan-Prednisone (VMP) vs Lenalidomide-Dexamethasone (Rd) and in the following up-dated with the introduction of the anti-CD38 mAb Daratumumab (Dara)...Patients were stratified according to treatment regimen, clinical response, and the treatment with the bone active agent zoledronic acid (ZA)... Overall, this study suggest that Bortezomib-based regimen exerts a significant and stronger inhibitory effect on bone resorption activity as compared to lenalidomide-based regimen in elderly NDMM patients."

Clinical • IO biomarker • P4 data • Hematological Malignancies • Multiple Myeloma • BGLAP

A Pilot Study of Romosozumab in Postmenopausal Women with Myeloma-Related Bone Disease and Osteoporosis (IMS 2026) - "During romo therapy, 4 were on maintenance therapy, 5 on daratumumab-based regimens with 2 proceeding to CART, and 1 on observation...All pts had prior zoledronic acid (ZA) with median time from last dose of ZA to romo start of 22 (range 4-58) mos... In our study, romo was well-tolerated and resulted in significant early increases in bone formation markers (P1NP, osteocalcin, BAP) compared to baseline. Our findings suggest that romo has positive anabolic effects in MM pts without negatively impacting anti-MM therapy."

Clinical • Hematological Malignancies • Multiple Myeloma • Orthopedics • Osteoporosis • Rheumatology

Myeloma Bone Disease: What Does a Deteriorating Osteocyte Lacuno-Canalicular Network Mean for Bone Recovery? (IMS 2026) - "Patients underwent whole-body low-dose CT imaging and bone marrow biopsy at baseline and 3 months post-induction +/- autograft (and zoledronic acid), alongside monthly fasting serum bone turnover markers... This pilot confirms that osteolytic lesions have the potential for repair , likely supported by myeloma-targeted therapies such as proteasome inhibitors. However, the bone quality when repair occurs is currently unknown. Our findings demonstrate that osteocyte LCN connectivity is significantly reduced following myeloma treatment, which is likely detrimental to bone repair."

Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • Orthopedics • SOST • TRAP

Inflammation vs. multiple AVN sites: a nuclear medicine evaluation in systemic allergic-immune syndrome - a case report. (PubMed, Ann Med Surg (Lond)) - "These findings enabled timely therapeutic intervention, including reassessment of corticosteroid use, institution of bisphosphonate therapy (zoledronic acid), and joint-protective rehabilitation, illustrating the direct clinical impact of advanced nuclear medicine imaging. The persistence of symptoms despite treatment highlights the refractory nature of multifocal corticosteroid-induced AVN and the need for continued multidisciplinary follow-up."

Journal • Allergic Bronchopulmonary Aspergillosis • Asthma • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Musculoskeletal Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology

Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials (ESMO 2024) - P2/3 | "We hypothesised that the Decipher 22-gene mRNA score (DS) predicts Doce benefit. DS were generated from whole transcriptome profiling with a clinical test (Veracyte) on tumor index cores from patients (pts) randomised 1:1 to ADT or ADT + Doce +/- zoledronic acid (ZA) in the STAMPEDE protocol (Oct 2005 - Mar 2013). High DS identifies synchronous M1 PC pts who benefit from Doce. DS is the 1st molecular classifier independent of metastatic volume to show a statistically significant interaction with Doce in directly randomised M1 PC pts."

Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Insights from the global REASSURE study (ESMO 2025) - P, P3 | "Incidence of fractures was slightly higher in ALL pts (10%) with fewer pts receiving concomitant BPAs (denosumab 28% and zoledronic acid 13%)...Table: 2401P ENZ/RAD (N=45) ALL Pts (N=1,472) Median time since initial diagnosis of bone metastases to study entry, months 14 23 Median time since castration resistant cancer to study entry, months 7 13 Extent of disease, % Bone only metastases 80 81 Bone metastases + lymph node only 9 13 Disease burden, % 20 metastases but not Superscan 18 20 Superscan 4 6 Laboratory values, median ALP (U/L) 131 133 PSA (ng/mL) 33 59 Prior abiraterone, % 40 48 Prior docetaxel, % 16 39 Prior Sipuleucel-T, % 18 9 Conclusions In this subgroup of pts treated with combined ENZ/RAD in a real-world setting, there was no new safety signal...Pts received ENZ/RAD earlier in the disease course based on time from mCRPC, time from initial diagnosis of bone metastases and prior docetaxel. Fracture incidence was low in ENZ/RAD, and the majority of pts..."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use. (PubMed, Cancers (Basel)) - "In HR+/HER2- MBC patients with bone-only disease, first-line CDK4/6 inhibitor therapy demonstrates a trend toward superior PFS. After correcting for key observational biases, the later line of therapy does not independently alter OS. These findings reinforce that first-line CDK4/6 inhibitor plus endocrine therapy remains the definitive standard of care, and later-line initiation should be reserved solely for select clinical scenarios where first-line use was not feasible."

Journal • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) (ESMO 2024) - P2/3, P3 | "We validated the fitted model using two comparisons from the STAMPEDE trial (SOC vs. SOC + docetaxel (A vs C) and SOC vs. SOC + zoledronic acid+ docetaxel (A vs E)). The model identified novel prognostic factors of OS in men with mHSPC. It offers the potential for classifying pts into risk groups useful in selecting men in future mHSPC trials. Further validation of this prognostic model of OS is warranted."

Clinical • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

The Role of Bisphosphonate and Simvastatin Combination on Therapeutic Response in Breast Cancer With Bone Metastasis Via Dicckopf-1 Pathway (clinicaltrials.gov) - P=N/A | N=35 | Completed | Sponsor: Indonesia University

New trial • Breast Cancer • Oncology • Solid Tumor • DKK1 • TRAP

Pregnancy and lactation-associated osteoporosis in a postpartum woman with twin pregnancy: a 5-year follow-up case report. (PubMed, Front Endocrinol (Lausanne)) - "She was treated with calcium carbonate, calcitriol, alfacalcidol, calcitonin, and intravenous zoledronic acid (initial 5 mg dose during admission, with a second 5 mg dose administered at 1-year follow-up)...This case highlights the importance of considering PLO in postpartum women with severe back pain, particularly in the presence of risk factors such as low BMI, inadequate calcium intake, vitamin D insufficiency, exclusive breastfeeding, and twin pregnancy. Early recognition and management can prevent prolonged morbidity and support continued improvement in bone health."

Journal • Back Pain • Lumbar Back Pain • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology

A Rare Case of Oligosecretory Multiple Myeloma With Intracranial Plasmacytoma. (PubMed, Cureus) - "Radiotherapy targeting the sphenoidal mass was initiated, combined with corticosteroid therapy and zoledronic acid for hypercalcemia; the neurological emergency and the patient's frailty led to favoring this local approach over standard systemic therapy...This case highlights the pivotal role of FLC assay in diagnosing OSMM when conventional techniques are negative, and the need for a multidisciplinary approach in cases of intracranial involvement. Biochemical (serial FLC) and radiological (brain MRI at three months, then every three to six months) follow-up remain recommended in the literature, as does high-performance liquid chromatography (HPLC), currently under validation for minimal residual disease detection - these points, however, remain general literature-based recommendations rather than conclusions drawn from our single observation."

Journal • Chordoma • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Lymphoma • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics • Pain • Plasmacytoma • Sarcoma • Septic Shock • Solid Tumor • Thrombocytopenia

Refractory Rebound Hypercalcemia Following Abrupt Denosumab Withdrawal in an Adult With Myeloma-Related Bone Disease: A Clinically Challenging Metabolic Surge (SOHO 2026) - "Her disease was in remission after induction therapy followed by autologous stem cell transplant; she was currently on maintenance lenalidomide...Multiple hospitalizations ensued, and her hypercalcemia proved refractory to hydration, calcitonin, and repeated zoledronic acid infusions... Rebound hypercalcemia is a rare side effect of denosumab in adults and stems from rapid restoration of osteoclastogenesis and accelerated bone resorption when RANKL inhibition abruptly ceases. Individuals with prolonged antiresorptive exposure or high-turnover bone disease are particularly vulnerable. Pooled safety data from the FDA reported that 0.7% of patients experience rebound hypercalcemia following discontinuation of denosumab across all tumor types."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial. (PubMed, Br J Cancer) - P3 | "Adding zoledronic acid did not improve clinical outcomes in ES."

Journal • P3 data • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor

A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial) (AACR 2024) - P1 | "Lymphodepletion with fludarabine 25mg/m2/day and cyclophosphamide 250mg/m2/day will given for 3 days and completed at least 2 days prior to the first cycle of treatment...Patients will receive intravenous zoledronic acid 1mg prior to each cellular infusion and subcutaneous IL-2 1x106 IU/m2 within 2 hours of each cellular infusion as pre-clinical data demonstrated cancer cell sensitisation and prolonged γδ T cell survival with these adjuncts...Adverse events, response rates (RECIST v1.1), survival outcomes and immunomonitoring (immune cell phenotyping and serum cytokine analysis) will be assessed. The trial is currently enrolling healthy donors; enrolment of patients at the first dose level will begin in February 2024.NCT05302037"

Clinical • Metastases • P1 data • Hematological Malignancies • Oncology • Solid Tumor • IL2 • NKG2D